Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 6
2009 9
2010 3
2011 1
2012 2
2013 1
2014 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.
Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JH, Orzalesi L, Bouma WH, van der Mijle HC, Nieuwenhuijzen GA, Veltkamp SC, Slaets L, Duez NJ, de Graaf PW, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JW, Belkacemi Y, Petignat P, Schinagl DA, Coens C, Messina CG, Bogaerts J, Rutgers EJ. Donker M, et al. Lancet Oncol. 2014 Nov;15(12):1303-10. doi: 10.1016/S1470-2045(14)70460-7. Epub 2014 Oct 15. Lancet Oncol. 2014. PMID: 25439688 Free PMC article. Clinical Trial.
Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors.
Romeo S, Debiec-Rychter M, Van Glabbeke M, Van Paassen H, Comite P, Van Eijk R, Oosting J, Verweij J, Terrier P, Schneider U, Sciot R, Blay JY, Hogendoorn PC; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Romeo S, et al. Clin Cancer Res. 2009 Jun 15;15(12):4191-8. doi: 10.1158/1078-0432.CCR-08-3297. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509155
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas.
Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, Guastalla JP, Bachelot T, Perol D, Chabaud S, Hogendoorn PC, Cassier P, Dufresne A, Blay JY; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Ray-Coquard I, et al. Cancer Res. 2009 Jul 1;69(13):5383-91. doi: 10.1158/0008-5472.CAN-08-3845. Epub 2009 Jun 23. Cancer Res. 2009. PMID: 19549917 Free PMC article.
Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial.
Straver ME, Meijnen P, van Tienhoven G, van de Velde CJ, Mansel RE, Bogaerts J, Duez N, Cataliotti L, Klinkenbijl JH, Westenberg HA, van der Mijle H, Snoj M, Hurkmans C, Rutgers EJ. Straver ME, et al. Ann Surg Oncol. 2010 Jul;17(7):1854-61. doi: 10.1245/s10434-010-0945-z. Epub 2010 Mar 19. Ann Surg Oncol. 2010. PMID: 20300966 Free PMC article. Clinical Trial.
Comparison of the sentinel node procedure between patients with multifocal and unifocal breast cancer in the EORTC 10981-22023 AMAROS Trial: identification rate and nodal outcome.
Donker M, Straver ME, van Tienhoven G, van de Velde CJ, Mansel RE, Litière S, Werutsky G, Duez NJ, Orzalesi L, Bouma WH, van der Mijle H, Nieuwenhuijzen GA, Veltkamp SC, Helen Westenberg A, Rutgers EJ. Donker M, et al. Eur J Cancer. 2013 Jun;49(9):2093-100. doi: 10.1016/j.ejca.2013.02.017. Epub 2013 Mar 19. Eur J Cancer. 2013. PMID: 23522754 Clinical Trial.
The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 "boost versus no boost" trial.
Poortmans PM, Collette L, Bartelink H, Struikmans H, Van den Bogaert WF, Fourquet A, Jager JJ, Hoogenraad W, Müller RP, Dubois JB, Bolla M, Van Der Hulst M, Wárlám-Rodenhuis CC, Pierart M, Horiot JC; EORTC Radiation Oncology and Breast Cancer Groups. Poortmans PM, et al. Cancer Radiother. 2008 Nov;12(6-7):565-70. doi: 10.1016/j.canrad.2008.07.014. Epub 2008 Aug 28. Cancer Radiother. 2008. PMID: 18760649 Clinical Trial.
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.
Le Cesne A, Van Glabbeke M, Verweij J, Casali PG, Findlay M, Reichardt P, Issels R, Judson I, Schoffski P, Leyvraz S, Bui B, Hogendoorn PC, Sciot R, Blay JY. Le Cesne A, et al. J Clin Oncol. 2009 Aug 20;27(24):3969-74. doi: 10.1200/JCO.2008.21.3330. Epub 2009 Jul 20. J Clin Oncol. 2009. PMID: 19620483 Free PMC article. Clinical Trial.
Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial.
Poortmans PM, Collette L, Horiot JC, Van den Bogaert WF, Fourquet A, Kuten A, Noordijk EM, Hoogenraad W, Mirimanoff RO, Pierart M, Van Limbergen E, Bartelink H; EORTC Radiation Oncology and Breast Cancer Groups. Poortmans PM, et al. Radiother Oncol. 2009 Jan;90(1):80-5. doi: 10.1016/j.radonc.2008.07.011. Epub 2008 Aug 15. Radiother Oncol. 2009. PMID: 18707785 Clinical Trial.
19 results